There are 2789 resources available
1081P - Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands
Presenter: Jesper Breeschoten
Session: ePoster Display
1082P - Phase I study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma
Presenter: Filip Janku
Session: ePoster Display
1083P - A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
Presenter: Alexander Shoushtari
Session: ePoster Display
1084P - PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma
Presenter: Caroline Robert
Session: ePoster Display
1085P - Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors
Presenter: Elizabeth Burton
Session: ePoster Display
1184P - Necroptosis establishes an inflammatory tumor immune microenvironment acting as tumor suppressor in lung adenocarcinoma
Presenter: Fabian Allmendinger
Session: ePoster Display
1185P - Induction immunotherapy in resectable non-small cell lung cancer harboring driver mutations: A multi-center retrospective study
Presenter: Chao Zhang
Session: ePoster Display
1186P - Study on possible mechanisms of HPD associated with the amplification of chromosome 11q13 in NSCLC
Presenter: Jie Lei
Session: ePoster Display
1187P - A mutation characteristics analysis of SMARCA4defSMARCA2wt in lung cancer
Presenter: Jisheng Li
Session: ePoster Display
1188P - Concurrent chemoradiotherapy with cisplatin + S-1 for locally advanced non-small cell lung cancer: IPD meta-analysis
Presenter: Yuri Taniguchi
Session: ePoster Display